Nyxoah Plans to Close Offering Around June 9
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
The offering is expected to close on or around June 9, subject to the satisfaction of customary closing conditions. Nyxoah intends to use the net proceeds from the offering (i) for expanding commercialization activities in the United States; (ii) to further finance research and development activities related to Genio system upgrades, re-designing its products for manufacturability and cost reduction initiatives, and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; (iii) to advance commercialization of the Genio system in its initial target markets outside of the United States and to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; and (iv) for other general corporate purposes, including, but not limited to, working capital, repayment of debt financing, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations. BofA acted as lead book running manager for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NYXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NYXH
Wall Street analysts forecast NYXH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.630
Low
5.82
Averages
10.41
High
13.00
Current: 1.630
Low
5.82
Averages
10.41
High
13.00
About NYXH
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026
- Extraordinary Meeting Details: Nyxoah is set to hold its extraordinary shareholders' meeting on July 9, 2026, at 2:00 PM CET at its headquarters in Belgium, allowing shareholders to participate remotely via video conference, thereby enhancing shareholder engagement and interaction.
- Capital Authorization Renewal Proposal: The agenda includes a proposal from the board to renew the authorization for capital increases over the next five years, aimed at providing financial support for the company's long-term growth and enhancing capital flexibility.
- Voting and Participation Requirements: Shareholders must register by June 25, 2026, and notify the company of their intention to participate by July 3, ensuring compliance and increasing the effectiveness of voting, which promotes active shareholder involvement.
- Transparency and Data Protection: The company commits to adhering to its privacy policy while processing personal data during the shareholders' meeting, ensuring the security and transparency of shareholder information, which enhances trust in the company.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance: Nyxoah SA issued 55,232,558 new shares in its underwritten public offering in the U.S., raising its total share capital to EUR 7,073,687, indicating active engagement in capital markets and financing capabilities.
- Total Voting Rights: As of June 10, 2026, Nyxoah has a total of 99,926,284 voting rights, all pertaining to ordinary shares, reflecting the company's transparency and compliance in shareholder structure.
- Convertible Bonds Information: The company currently has 225 convertible bonds with a nominal value of EUR 83,000 each, which could potentially convert into 12,618,243 voting rights, showcasing opportunities for capital expansion.
- Subscription Rights Status: As of May 31, 2026, Nyxoah has 3,322,832 subscription rights that have not yet been issued, indicating flexibility in future financing and potential enhancement of shareholder value.
See More
Nyxoah Secures $110 Million Financing to Accelerate U.S. Launch
- Significant Financing: Nyxoah has successfully completed a $95 million equity financing and anticipates receiving a $15 million second tranche from the European Investment Bank loan by the end of June 2026, totaling $110 million in new capital, which provides robust financial support for the company's expansion into the U.S. market.
- Commercialization Acceleration: This financing will expedite the commercialization of the Genio system in the U.S., where the company has established 40 sales representatives under an experienced commercial leadership team, aiming to enhance market penetration and meet the growing customer demand.
- Strategic Leadership Transition: CEO Olivier Taelman stated that this financing marks a defining moment for the company, enabling it to build on the strong momentum from its first two commercial quarters in the U.S. and further drive the market launch of Genio, thereby enhancing its competitiveness in the obstructive sleep apnea sector.
- Investor Confidence Boost: Chairman Robert Taub emphasized that the strong participation from both new and existing investors is a powerful endorsement of Genio technology and the company's strategy, securing a solid financial foundation that lays the groundwork for long-term value creation for shareholders.
See More
Nyxoah Plans $95 Million Public Offering to Expand U.S. Operations
- Offering Details: Nyxoah is offering over 55 million ordinary shares to investors in the U.S. and Europe to raise $95 million, with a share price of $1.72 or €1.48, representing over a 40% discount to the last closing price, indicating strong market reactions to its valuation.
- Underwriter Option: Underwriters have the option to purchase an additional 8.3 million ordinary shares at the offering price within 30 days, providing the company with flexibility for further financing and potentially boosting market confidence.
- U.S. Expansion Plans: The funds raised will primarily be used to expand commercialization efforts in the U.S., and the company is seeking a U.S.-based CEO to enhance sales of its flagship product, Genio, demonstrating its commitment to the U.S. market.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment regarding NYXH shifted from 'bearish' to 'extremely bullish' in the past 24 hours, reflecting optimistic expectations for the company's future despite its stock price having fallen over 80% in the last year.
See More
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
- Offering Size and Pricing: Nyxoah's public offering in the U.S. is priced at $1.72 per share, with expected gross proceeds of approximately $95 million, reflecting strong market interest in its OSA treatment technology and reinforcing its position in the medical technology sector.
- Planned Use of Funds: The proceeds will be allocated to expanding commercialization efforts in the U.S., further financing upgrades to the Genio system, and supporting clinical research for OSA patients, aiming to enhance product competitiveness and drive long-term growth for the company.
- Underwriters and Market Response: With BofA Securities acting as the lead underwriter, the offering is expected to close on June 9, 2026, indicating strong market confidence in Nyxoah and enhancing the company's activity in capital markets.
- Strategic Development and Collaboration Opportunities: Nyxoah plans to leverage the proceeds to explore potential collaborations in the field of OSA monitoring and diagnostics, demonstrating the company's strategic commitment to innovation and market expansion.
See More
Nyxoah Launches Proposed Public Offering in the U.S.
- Public Offering Announcement: Nyxoah has launched a proposed underwritten public offering of ordinary shares in the U.S., with all shares sold by the company and underwriters expected to receive a 30-day option to purchase an additional 15%, indicating confidence in market demand.
- Clear Use of Proceeds: The net proceeds from the offering are intended to support the commercialization of the Genio obstructive sleep apnea treatment system in the U.S. and other markets, fund R&D activities, and cover general corporate purposes, including working capital and potential debt repayment, reflecting the company's strategic growth planning.
- Market Condition Dependencies: The transaction remains subject to market and other conditions, showcasing the company's cautious approach in the current economic environment, which may affect investor confidence and market reactions.
- Undisclosed Size and Pricing: Although the company has not disclosed the size or pricing of the offering, this initiative could impact its stock performance, prompting investors to monitor subsequent information to assess investment risks and opportunities.
See More
Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026
- Extraordinary Meeting Details: Nyxoah is set to hold its extraordinary shareholders' meeting on July 9, 2026, at 2:00 PM CET at its headquarters in Belgium, allowing shareholders to participate remotely via video conference, thereby enhancing shareholder engagement and interaction.
- Capital Authorization Renewal Proposal: The agenda includes a proposal from the board to renew the authorization for capital increases over the next five years, aimed at providing financial support for the company's long-term growth and enhancing capital flexibility.
- Voting and Participation Requirements: Shareholders must register by June 25, 2026, and notify the company of their intention to participate by July 3, ensuring compliance and increasing the effectiveness of voting, which promotes active shareholder involvement.
- Transparency and Data Protection: The company commits to adhering to its privacy policy while processing personal data during the shareholders' meeting, ensuring the security and transparency of shareholder information, which enhances trust in the company.
See More
Nyxoah Discloses Voting Rights and Share Information
- Share Issuance: Nyxoah SA issued 55,232,558 new shares in its underwritten public offering in the U.S., raising its total share capital to EUR 7,073,687, indicating active engagement in capital markets and financing capabilities.
- Total Voting Rights: As of June 10, 2026, Nyxoah has a total of 99,926,284 voting rights, all pertaining to ordinary shares, reflecting the company's transparency and compliance in shareholder structure.
- Convertible Bonds Information: The company currently has 225 convertible bonds with a nominal value of EUR 83,000 each, which could potentially convert into 12,618,243 voting rights, showcasing opportunities for capital expansion.
- Subscription Rights Status: As of May 31, 2026, Nyxoah has 3,322,832 subscription rights that have not yet been issued, indicating flexibility in future financing and potential enhancement of shareholder value.
See More
Nyxoah Secures $110 Million Financing to Accelerate U.S. Launch
- Significant Financing: Nyxoah has successfully completed a $95 million equity financing and anticipates receiving a $15 million second tranche from the European Investment Bank loan by the end of June 2026, totaling $110 million in new capital, which provides robust financial support for the company's expansion into the U.S. market.
- Commercialization Acceleration: This financing will expedite the commercialization of the Genio system in the U.S., where the company has established 40 sales representatives under an experienced commercial leadership team, aiming to enhance market penetration and meet the growing customer demand.
- Strategic Leadership Transition: CEO Olivier Taelman stated that this financing marks a defining moment for the company, enabling it to build on the strong momentum from its first two commercial quarters in the U.S. and further drive the market launch of Genio, thereby enhancing its competitiveness in the obstructive sleep apnea sector.
- Investor Confidence Boost: Chairman Robert Taub emphasized that the strong participation from both new and existing investors is a powerful endorsement of Genio technology and the company's strategy, securing a solid financial foundation that lays the groundwork for long-term value creation for shareholders.
See More
Nyxoah Plans $95 Million Public Offering to Expand U.S. Operations
- Offering Details: Nyxoah is offering over 55 million ordinary shares to investors in the U.S. and Europe to raise $95 million, with a share price of $1.72 or €1.48, representing over a 40% discount to the last closing price, indicating strong market reactions to its valuation.
- Underwriter Option: Underwriters have the option to purchase an additional 8.3 million ordinary shares at the offering price within 30 days, providing the company with flexibility for further financing and potentially boosting market confidence.
- U.S. Expansion Plans: The funds raised will primarily be used to expand commercialization efforts in the U.S., and the company is seeking a U.S.-based CEO to enhance sales of its flagship product, Genio, demonstrating its commitment to the U.S. market.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment regarding NYXH shifted from 'bearish' to 'extremely bullish' in the past 24 hours, reflecting optimistic expectations for the company's future despite its stock price having fallen over 80% in the last year.
See More
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
- Offering Size and Pricing: Nyxoah's public offering in the U.S. is priced at $1.72 per share, with expected gross proceeds of approximately $95 million, reflecting strong market interest in its OSA treatment technology and reinforcing its position in the medical technology sector.
- Planned Use of Funds: The proceeds will be allocated to expanding commercialization efforts in the U.S., further financing upgrades to the Genio system, and supporting clinical research for OSA patients, aiming to enhance product competitiveness and drive long-term growth for the company.
- Underwriters and Market Response: With BofA Securities acting as the lead underwriter, the offering is expected to close on June 9, 2026, indicating strong market confidence in Nyxoah and enhancing the company's activity in capital markets.
- Strategic Development and Collaboration Opportunities: Nyxoah plans to leverage the proceeds to explore potential collaborations in the field of OSA monitoring and diagnostics, demonstrating the company's strategic commitment to innovation and market expansion.
See More
Nyxoah Launches Proposed Public Offering in the U.S.
- Public Offering Announcement: Nyxoah has launched a proposed underwritten public offering of ordinary shares in the U.S., with all shares sold by the company and underwriters expected to receive a 30-day option to purchase an additional 15%, indicating confidence in market demand.
- Clear Use of Proceeds: The net proceeds from the offering are intended to support the commercialization of the Genio obstructive sleep apnea treatment system in the U.S. and other markets, fund R&D activities, and cover general corporate purposes, including working capital and potential debt repayment, reflecting the company's strategic growth planning.
- Market Condition Dependencies: The transaction remains subject to market and other conditions, showcasing the company's cautious approach in the current economic environment, which may affect investor confidence and market reactions.
- Undisclosed Size and Pricing: Although the company has not disclosed the size or pricing of the offering, this initiative could impact its stock performance, prompting investors to monitor subsequent information to assess investment risks and opportunities.
See More
